Literature DB >> 8267486

Gram-positive organisms and sepsis.

R C Bone1.   

Abstract

In recent years, the importance of gram-negative organisms in the genesis of sepsis has been emphasized. However, this emphasis may no longer be correct; recent studies show an increasing incidence of gram-positive sources of sepsis, and its is possible that these cases may predominate in the coming years. This increase results from more than just a greater prevalence of infection--it appears that gram-positive organisms may also be more virulent in fomenting the disease, as can be evidenced by the emergence of streptococcal toxic shock syndrome and the resurgence of acute rheumatic fever. This may result from the ability of gram-positive organisms to produce more inflammation-causing cell wall constituents, as well as unbound exotoxins. Despite the recent emphasis on gram-negative causes, sepsis resulting from gram-positive sources is increasingly common. Research on these causes of sepsis should be encouraged.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8267486

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  64 in total

Review 1.  The role of antimicrobial peptides in animal defenses.

Authors:  R E Hancock; M G Scott
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-01       Impact factor: 11.205

2.  Antimicrobial properties of distinctin in an experimental model of MRSA-infected wounds.

Authors:  O Simonetti; O Cirioni; R Ghiselli; G Goteri; F Orlando; L Monfregola; S De Luca; A Zizzi; C Silvestri; G Veglia; A Giacometti; M Guerrieri; A Offidani; A Scaloni
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-06-23       Impact factor: 3.267

3.  Human monocyte receptors involved in tumor necrosis factor responses to group B streptococcal products.

Authors:  M Cuzzola; G Mancuso; C Beninati; C Biondo; C von Hunolstein; G Orefici; T Espevik; T H Flo; G Teti
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

Review 4.  The difficulties of clinical trials evaluating therapeutic agents in patients with severe sepsis.

Authors:  T C Hall; D K Bilku; D Al-Leswas; C Horst; A R Dennison
Journal:  Ir J Med Sci       Date:  2011-11-08       Impact factor: 1.568

5.  A mutant of staphylococcal enterotoxin C devoid of bacterial superantigenic activity elicits a Th2 immune response for protection against Staphylococcus aureus infection.

Authors:  Dong-Liang Hu; Jing-Chun Cui; Katsuhiko Omoe; Hiroshi Sashinami; Yuichi Yokomizo; Kunihiro Shinagawa; Akio Nakane
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

6.  New approaches to sepsis: molecular diagnostics and biomarkers.

Authors:  Konrad Reinhart; Michael Bauer; Niels C Riedemann; Christiane S Hartog
Journal:  Clin Microbiol Rev       Date:  2012-10       Impact factor: 26.132

7.  The cell wall components peptidoglycan and lipoteichoic acid from Staphylococcus aureus act in synergy to cause shock and multiple organ failure.

Authors:  S J De Kimpe; M Kengatharan; C Thiemermann; J R Vane
Journal:  Proc Natl Acad Sci U S A       Date:  1995-10-24       Impact factor: 11.205

8.  Delayed circulatory failure due to the induction of nitric oxide synthase by lipoteichoic acid from Staphylococcus aureus in anaesthetized rats.

Authors:  S J De Kimpe; M L Hunter; C E Bryant; C Thiemermann; J R Vane
Journal:  Br J Pharmacol       Date:  1995-03       Impact factor: 8.739

9.  Structure-activity relationships of antimicrobial and lipoteichoic acid-sequestering properties in polyamine sulfonamides.

Authors:  Hemamali J Warshakoon; Mark R Burns; Sunil A David
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

10.  The phosphatidylinositol 3-kinase/protein kinase B signaling pathway is activated by lipoteichoic acid and plays a role in Kupffer cell production of interleukin-6 (IL-6) and IL-10.

Authors:  Maria K Dahle; Gunhild Øverland; Anders E Myhre; Jon Fredrik Stuestøl; Thomas Hartung; Claus Danckert Krohn; Øystein Mathiesen; Jacob E Wang; Ansgar O Aasen
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.